During the recent session, uniQure N.V (NASDAQ:QURE)’s traded shares were 9.09 million, with the beta value of the company hitting 0.21. At the last check today, the stock’s price was $13.05, reflecting an intraday gain of 39.03% or $3.66. The 52-week high for the QURE share is $19.18, that puts it down -46.97 from that peak though still a striking 71.42% gain since the share price plummeted to a 52-week low of $3.73. The company’s market capitalization is $705.95M, and the average intraday trading volume over the past 10 days was 1.26 million shares, and the average trade volume was 1.10 million shares over the past three months.
uniQure N.V (QURE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.29. QURE has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.95.
uniQure N.V (NASDAQ:QURE) trade information
uniQure N.V (QURE) registered a 39.03% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 39.03% in intraday trading to $13.05, hitting a weekly high. The stock’s 5-day price performance is 52.33%, and it has moved by -7.02% in 30 days. Based on these gigs, the overall price performance for the year is 177.76%. The short interest in uniQure N.V (NASDAQ:QURE) is 4.39 million shares and it means that shorts have 3.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $27, which implies an increase of 51.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $24 and $30 respectively. As a result, QURE is trading at a discount of -129.89% off the target high and -83.91% off the low.
uniQure N.V (QURE) estimates and forecasts
In the rating firms’ projections, revenue will increase 44.51% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.04M as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 6.83M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 7.87M and 10.32M respectively. In this case, analysts expect current quarter sales to shrink by -23.25% and then drop by -33.76% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -9.66%. While earnings are projected to return 20.69% in 2025, the next five years will return 33.41% per annum.
QURE Dividends
uniQure N.V is due to release its next quarterly earnings on 2025-Feb-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
uniQure N.V (NASDAQ:QURE)’s Major holders
uniQure N.V insiders own 8.59% of total outstanding shares while institutional holders control 78.07%, with the float percentage being 85.41%. VESTAL POINT CAPITAL, LP is the largest shareholder of the company, while 166.0 institutions own stock in it. As of 2024-06-30, the company held over 4.75 million shares (or 9.7692% of all shares), a total value of $21.28 million in shares.
The next largest institutional holding, with 2.65 million shares, is of NANTAHALA CAPITAL MANAGEMENT, LLC’s that is approximately 5.4511% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $11.87 million.
Also, the Mutual Funds coming in first place with the largest holdings of uniQure N.V (QURE) shares are abrdn Healthcare Investors and Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND . Data provided on Dec 31, 2024 indicates that abrdn Healthcare Investors owns about 812.69 shares. This amounts to just over 1.50 percent of the company’s overall shares, with a $10.41 million market value. The same data shows that the other fund manager holds slightly less at 733.5, or about 1.36% of the stock, which is worth about $9.4 million.
